Telaglenastat hydrochloride clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses telaglenastat hydrochloride is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2019 | 3 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses telaglenastat hydrochloride is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03872427Written as Telaglenastat Hydrochloride
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT03831932Written as Telaglenastat Hydrochloride
- Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04250545Written as Telaglenastat Hydrochloride
- Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic AstrocytomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03528642Written as Telaglenastat Hydrochloride
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03798678Written as Telaglenastat Hydrochloride
Codes
What other systems call telaglenastat hydrochloride · ClinicalTrials.gg INT016060
- UNII (FDA) B33561JJ61TELAGLENASTAT HYDROCHLORIDEOne source FDA
- NCI Thesaurus C150413Telaglenastat HydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B33561JJ61 | TELAGLENASTAT HYDROCHLORIDE | One source FDA |
| NCI Thesaurus | C150413 | Telaglenastat Hydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.